Patent US4025629A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4025629A Expired / Lapsed US ⏱️ 0.0 years remaining

P-(trifluoromethylquinolylamino)benzamides, pharmaceutical dosage forms and method of treatment

Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-03-21
•
Granted: 1977-05-24
•
Expires: 1995-03-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel p-(trifluoromethylquinolylamino)benzamides are provided, for example, p-[(7-trifluoromethyl-4-quinolyl)-amino]-N,N-(3-methyl-3-azapentamethylene)benzamide and 1-[p-[[7-(trifluoromethyl)-4-quinolyl]amino]benzoyl]piperazine dihydrochloride. Also provided are pharmaceutical dosage unit forms for systemic administration and methods for their systemic administration. The compound, dosage unit forms and methods of systemic administration are useful in obtaining antihypertensive and anti-anxiety effects in mammals.

Inventors

  • 👤 Charles E. Coverdale

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 09:14
CPC Classifications
C; C07; C07D; C07D215/00; C07D215/02; C07D215/16; C07D215/38; C07D215/42; C07D215/44

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 1 words
p-[(7-trifluoromethyl-4-quinolyl)amino]-N,N-(3-methyl-3-azapentamethylene)benzamide.
Claim 2
Dependent Claim 1 words
p-[(7-trifluoromethyl-4-quinolyl)amino]-N,N-(3-methyl-3-azapentamethylene)benzamide.
Claim 3
Dependent Claim 2 words
1-[p-[[(7-trifluoromethyl)-4-quinolyl]-amino]-benzoyl]piperazine dihydrochloride.
Claim 4
Dependent Claim 2 words
1-[p-[[(7-trifluoromethyl)-4-quinolyl]-amino]-benzoyl]piperazine dihydrochloride.
Claim 5
Dependent Claim 51 words
A pharmaceutical dosage unit form adapted to systemic administration to obtain anti-hypertensive and anti-anxiety effects consisting essentially of an effective non-toxic amount for said effects within the range of from about 10 mg. to about 1000 mg. of p-[(7-trifluoromethyl-4-quinolyl)amino]-N,N-(3-methyl-3-azapentamethylene)benzamide in combination with pharmaceutical means which adapt the compound for systemic administration.
Claim 6
Dependent Claim 51 words
A pharmaceutical dosage unit form adapted to systemic administration to obtain anti-hypertensive and anti-anxiety effects consisting essentially of an effective non-toxic amount for said effects within the range of from about 10 mg. to about 1000 mg. of p-[(7-trifluoromethyl-4-quinolyl)amino]-N,N-(3-methyl-3-azapentamethylene)benzamide in combination with pharmaceutical means which adapt the compound for systemic administration.
Claim 7
Dependent Claim 52 words
A pharmaceutical dosage unit form adapted to systemic administration to obtain antihypertensive and anti-anxiety effects consisting essentially of an effective non-toxic amount for said effects within the range of from about 10 mg. to about 1000 mg. of 1-[p-[[(7-trifluoromethyl-4-quinolyl]amino]benzoyl]piperazine dihydrochloride in combination with pharmaceutical means which adapt the compound for systemic administration.
Claim 8
Dependent Claim 52 words
A pharmaceutical dosage unit form adapted to systemic administration to obtain antihypertensive and anti-anxiety effects consisting essentially of an effective non-toxic amount for said effects within the range of from about 10 mg. to about 1000 mg. of 1-[p-[[(7-trifluoromethyl-4-quinolyl]amino]benzoyl]piperazine dihydrochloride in combination with pharmaceutical means which adapt the compound for systemic administration.
Claim 9
Independent Claim 73 words
A method of obtaining antihypertensive and anti-anxiety effects in a mammal which consists essentially of administering systemically to the mammal a pharmaceutical dosage unit form supplying an effective non-toxic amount for antihypertensive and anti-anxiety effects of p-[(7-trifluoromethyl-4-quinolyl)amino]-N,N-(3-methyl-3-azapentamethylene)-benzamide or the pharmacologically acceptable acid addition salts thereof wherein the amount of compound administered is within the range of from about 0.1 mg. per kg. to about 15 mg. per kg. of weight of the mammal.
Claim 10
Independent Claim 73 words
A method of obtaining antihypertensive and anti-anxiety effects in a mammal which consists essentially of administering systemically to the mammal a pharmaceutical dosage unit form supplying an effective non-toxic amount for antihypertensive and anti-anxiety effects of p-[(7-trifluoromethyl-4-quinolyl)amino]-N,N-(3-methyl-3-azapentamethylene)-benzamide or the pharmacologically acceptable acid addition salts thereof wherein the amount of compound administered is within the range of from about 0.1 mg. per kg. to about 15 mg. per kg. of weight of the mammal.
Claim 11
Independent Claim 66 words
A method of obtaining antihypertensive and anti-anxiety effects in a mammal which consists essentially of administering systemically to the mammal a pharmaceutical dosage unit form supplying an effective non-toxic amount for antihypertensive and anti-anxiety effects of 1-[p-[[(7-trifluoromethyl)-4-quinolyl]amino]benzoyl]piperazine dihydrochloride wherein the amount of compound administered is within the range of from about 0.1 mg. per kg. to about 15 mg. per kg. of weight of the mammal.
Claim 12
Independent Claim 66 words
A method of obtaining antihypertensive and anti-anxiety effects in a mammal which consists essentially of administering systemically to the mammal a pharmaceutical dosage unit form supplying an effective non-toxic amount for antihypertensive and anti-anxiety effects of 1-[p-[[(7-trifluoromethyl)-4-quinolyl]amino]benzoyl]piperazine dihydrochloride wherein the amount of compound administered is within the range of from about 0.1 mg. per kg. to about 15 mg. per kg. of weight of the mammal.

References Cited (Backward Citations)

US2940974A Cited
US3632761A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-05-23 1980-11-22 1981-05-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-05-23 1984-11-22 1985-05-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-05-23 1988-11-22 1989-05-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag